CytoMed Acquires UK T Cell Technology to Advance Cancer Treatments in…

Sarah J · 2025-12-26T16:08:13.000Z

Singapore-based biopharmaceutical company CytoMed Therapeutics Limited has completed the acquisition of a next-generation allogeneic gamma delta T cell technology, known as TCB-002 , from UK-based TC BioPharm Limited, a subsidiary of TC BioPharm (Holdings) PLC. The acquisition, executed with full payment in November 2025, positions CytoMed to accelerate development of affordable donor-derived cell-based immunotherapies targeting both blood and solid cancers in China and India. The TCB-002 technology will complement CytoMed’s strategy to establish a non-viral gamma delta T cell immunotherapy platform that provides off-the-shelf treatment options with advantages in accessibility, treatment speed and cost over traditional autologous therapies. Previous clinical progress includes Phase I trials in Europe and an orphan drug designation from the U.S. Food and Drug Administration for treatment of Acute Myeloid Leukemia. CytoMed is engaged in advanced discussions with prospective partners to jointly develop and commercialise new manufacturing approaches that can be more easily deployed in China and India, including manufacturing methods using cytokines rather than live cells, which can address regulatory and logistical challenges in the region. This acquisition aligns with growing global interest in cell-based therapies, particularly in Asia, as companies seek to expand access to cutting-edge treatments while managing costs and regulatory complexities. CytoMed’s move reflects an important step in expanding immunotherapy innovation for markets with rising cancer incidence and strong demand for novel treatment options. #StartupEuropeIndiaNetwork #India #Tech #MarketExpansion #Science #AI #Infrastructure #Biotech #Immunotherapy #TCellTherapy #CancerTreatment

Member Login Get Access

CytoMed Acquires UK T Cell Technology to Advance Cancer Treatments in… | SEINET